Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex

Neuropsychopharmacology

Volumn 23, Issue 3, 2000, Pages 250-262

  Zhang, Wei ^a   Perry, Kenneth W ^a   Wong, David T ^a   Potts, Brian D ^a   Bao, Jingqi ^a   Tollefson, Gary D ^a   Bymaster, Frank P ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Depression; Dopamine; Fluoxetine; Norepinephrine; Olanzapine; Serotonin

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; BRAIN MONOAMINE; CLOZAPINE; DOPAMINE; FLUOXETINE; HALOPERIDOL; NEUROLEPTIC AGENT; NORADRENALIN; NORFLUOXETINE; OLANZAPINE; RISPERIDONE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ANIMAL EXPERIMENT; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DEPRESSION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG MECHANISM; DRUG POTENTIATION; MALE; MICRODIALYSIS; NEUROTRANSMITTER RELEASE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRAIN; DOPAMINE; DRUG SYNERGISM; EXTRACELLULAR SPACE; FLUOXETINE; MALE; MICRODIALYSIS; NOREPINEPHRINE; PIRENZEPINE; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; STIMULATION, CHEMICAL;

EID: 0034285086     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(00)00119-6     Document Type: Article

References (45)

1. Amsterdam J.D., Hornig-Rohan M. Treatment algorithms in treatment-resistant depression. Psychiatry Clin North Am. 19:1996;371-386.
2. Beasley C.M. Jr., Sanger T., Satterlee W., Tollefson G., Tran P., Hamilton S. Olanzapine versus placebo. Results of a double-blind, fixed-dose olanzapine trial Psychopharmacology. 124:1996;159-167.
3. Berman K.F., Weinberger D.R. The prefrontal cortex in schizophrenia and other neuropsychiatric diseases. In vivo physiological correlates of cognitive deficits Prog Brain Res. 85:1990;521-537.
4. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., Seeman P., Wong D.T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 14:1996;87-96.
5. Bymaster F.P., Rasmussen K., Calligaro D.O., Nelson D.L., DeLapp N.W., Wong D.T., Moore N.A. In vitro and in vivo biochemistry of olanzapine. A novel, atypical antipsychotic drug J Clin Psychiatry. 58:1997;28-36.
6. Dreshfield L.J., Wong D.T., Perry K.W., Engleman E.A. Enhancement of fluoxetine-dependent increase of extracellular serotonin (5-HT) levels by (-)-pindolol, an antagonist at 5-HT1A receptors. Neurochem Res. 21:1996;557-562.
7. Gobert A., Rivet J.M., Cistarelli J.M., Millan M.J. Buspirone enhances duloxetine- and fluoxetine-induced increases in dialysate levels of dopamine and noradrenaline, but not serotonin, in the frontal cortex of freely moving rats. J Neurochem. 68:1997;1326-1329.
8. Goldman-Rakic P.S. The prefrontal landscape. Implications of functional architecture for understanding human mentation and the central executive. Philosophical Transactions of the Royal Society of London - Series B Biol Sci. 351:1996;1445-1453.
9. Hertel P., Nomikos G.G., Iurlo M., Svensson T.H. Risperidone. regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain Psychopharmacology. 124:1996;74-86.
10. Hertel P., Nomikos G.G., Schilstrom B., Arborelius L., Svensson T.H. Risperidone dose-dependently increases extracellular concentrations of serotonin in the rat frontal cortex. Role of alpha 2-adrenoceptor antagonism Neuropsychopharmacology. 17:1997;44-55.
11. Heym J., Koe B.K. Pharmacology of sertraline. A review J Clin Psychiatry. 49:1988;40-45.
12. Ichikawa J., Kuroki T., Dai J., Meltzer H.Y. Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. Eur J Pharmacol. 351:1998;163-171.
13. Kessler R.C., McGonagle K.A., Zhao S., Nelson C.B., Hughes M., Eshleman S., Wittchen H.U., Kendler K.S. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 51:1994;8-19.
14. Koe B.K., Weissman A., Welch W.M., Browne R.G. Sertraline, 1S,4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin. J Pharmacol Exp Ther. 226:1983;686-700.
15. Kuroki T., Meltzer H.Y., Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther. 288:1999;774-781.
16. Li X.M., Perry K.W., Wong D.T., Bymaster F.P. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology. 136:1998;153-161.
17. Maes M., Meltzer H.Y. The serotonin hypothesis of major depression. Bloom F.E., Kupfer D.J. Psychopharmacology. The Fourth Generation of Progress:1995;933-944 Raven Press Ltd, New York, NY.
18. Millan M.J., Dekeyne A., Gobert A. Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology. 37:1998;953-955.
19. Nelson J.C. Treatment of antidepressant nonresponders. Augmentation or switch? J Clin Psychiatry. 59:1998;35-41.
20. Nierenberg A.A., Amsterdam J.D. Treatment-resistant depression. Definition and treatment approaches J Clin Psychiatry. 51:1990;39-47.
21. Palvimaki E.P., Roth B.L., Majasuo H., Laakso A., Kuoppamaki M., Syvalahti E., Hietala J. Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor. Psychopharmacology. 126:1996;234-240.
22. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Academic Press, San Diego, CA.
23. Perry K.W., Fuller R.W. Effect of fluoxetine on serotonin and dopamine concentration in microdialysis fluid from rat striatum. Life Sci. 50:1992;1683-1690.
24. 4 and microdialysis in conscious rats. J Neural Transm. 104:1997;953-966.
25. Pessia M., Jiang Z.G., North R.A., Johnson S.W. Actions of 5-hydroxytryptamine on ventral tegmental area neurons of the rat in vitro. Brain Res. 654:1994;324-330.
26. Roose S.P., Glassman A.H., Walsh B.T., Woodring S. Tricyclic nonresponders. Phenomenology and treatment Am J Psychiatry. 143:1986;345-348.
27. Rothschild A.J., Bates K.S., Boehringer K.L., Syed A. Olanzapine response in psychotic depression. J Clin Psychiatry. 60:1999;116-118.
28. Schatzberg A.F., Schildkraut J. Recent studies on norepinephrine systems in mood disorders. Bloom F.E., Kupfer D.J. Psychopharmacology. The Fourth Generation of Progress:1995;911-920 Raven Press Ltd, New York, NY.
29. Schmidt C.J., Fadayel G.M. The selective 5-HT2A receptor antagonist, MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat. Eur J Pharmacol. 273:1995;273-279.
30. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs. In vitro and in vivo receptor binding Psychopharmacology. 124:1996;57-73.
31. Sorensen S.M., Kehne J.H., Fadayel G.M., Humphreys T.M., Ketteler H.J., Sullivan C.K., Taylor V.L., Schmidt C.J. Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic. Behavioral, electrophysiological and neurochemical studies J Pharmacol Exp Ther. 266:1993;684-691.
32. Sprouse J., Clarke T., Reynolds L., Heym J., Rollema H. Comparison of the effects of sertraline and its metabolite desmethylsertraline on blockade of central 5-HT reuptake in vivo. Neuropsychopharmacology. 14:1996;225-231.
33. Thase M.E., Rush A.J. Treatment-resistant depression. Bloom F.E., Kupfler D.J. Psychopharmacology. The Fourth Generation of Progress:1995;1081-1097 Raven Press, New York, NY.
34. Thomas D.N., Nutt D.J., Holman R.B. Sertraline, a selective serotonin reuptake inhibitor modulates extracellular noradrenaline in the rat frontal cortex. J Psychopharmacol. 12:1998;366-370.
35. Tohen M, Shelton R, Tollefson GD, Stahl S, Jacobs T, Gannon KS (1999): Olanzapine plus fluoxetine: Double-blind and open-label results in treatment-resistant major depressive disorder. 12th European College of Neuropsychopharmacology Congress (ECNP), London, UK, September 21-25, 1999.
36. Tollefson G.D., Beasley C.M. Jr., Tran P.V., Street J.S., Krueger J.A., Tamura R.N., Graffeo K.A., Thieme M.E. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders. Results of an international collaborative trial Am J Psychiatry. 154:1997;457-465.
37. Tollefson G.D., Sanger T.M., Lu Y., Thieme M.E. Depressive signs and symptoms in schizophrenia. A prospective blinded trial of olanzapine and haloperidol Arch Gen Psychiatry. 55:1998;250-258. [published erratum appears in Arch Gen Psychiatry 1998; 55(11):1052].
38. Volonte M., Monferini E., Cerutti M., Fodritto F., Borsini F. BIMG 80, a novel potential antipsychotic drug. Evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex J Neurochem. 69:1997;182-190.
39. Weinberger D.R., Berman K.F. Prefrontal function in schizophrenia. Confounds and controversies. Philosophical Transactions of the Royal Society of London - Series B Biol Sci. 351:1996;1495-1503.
40. Westerink B.H., de Boer P., de Vries J.B., Kruse C.G., Long S.K. Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain. Eur J Pharmacol. 361:1998;27-33.
41. Willner P. Dopaminergic mechanism in depression and mania. Bloom F.E., Kupfer D.J. Psychopharmacology. The Fourth Generation of Progress:1995;921-931 Raven Press, New York, NY.
42. Wong D.T., Bymaster F.P., Engleman E.A. Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug. Twenty years since its first publication Life Sci. 57:1995;411-441.
43. Wong D.T., Bymaster F.P., Reid L.R., Threlkeld P.G. Fluoxetine and two other serotonin uptake inhibitors without affinity for neuronal receptors. Biochem Pharmacol. 32:1983;1287-1293.
44. Wong D.T., Threlkeld P.G., Robertson D.W. Affinities of fluoxetine, its enantiomers, and other inhibitors of serotonin uptake for subtypes of serotonin receptors. Neuropsychopharmacology. 5:1991;43-47.
45. Zhang W., Bymaster F.P. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacology. 141:1999;267-278.